# EDGAR Filing Document

**Accession Number:** 0001563411
**File Stem:** 0001563411-26-000174
**Filing Date:** 2026-5
**Character Count:** 17613
**Document Hash:** 65b1db3433d9a48bd7f9f3fd5a7e5e92
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001563411-26-000174.hdr.sgml**: 20260521

**ACCESSION NUMBER**: 0001563411-26-000174

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260521

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260521

**DATE AS OF CHANGE**: 20260521

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CONSTELLIUM SE
- **CENTRAL INDEX KEY:** 0001563411
- **STANDARD INDUSTRIAL CLASSIFICATION:** SECONDARY SMELTING & REFINING OF NONFERROUS METALS [3341]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35931
- **FILM NUMBER:** 261007996

**BUSINESS ADDRESS:**
- **STREET 1:** WASHINGTON PLAZA
- **STREET 2:** 40-44 RUE WASHINGTON
- **CITY:** PARIS
- **STATE:** I0
- **ZIP:** 75008
- **BUSINESS PHONE:** 33-1-73-01-46-51

**MAIL ADDRESS:**
- **STREET 1:** WASHINGTON PLAZA
- **STREET 2:** 40-44 RUE WASHINGTON
- **CITY:** PARIS
- **STATE:** I0
- **ZIP:** 75008

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Constellium SE
- **DATE OF NAME CHANGE:** 20190628

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Constellium N.V.
- **DATE OF NAME CHANGE:** 20130521

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Constellium Holdco B.V.
- **DATE OF NAME CHANGE:** 20121130

?xml version='1.0' encoding='ASCII'? cstm-20260521

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): May 21, 2026**

## Constellium SE
**(Exact name of registrant as specified in its charter)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **France** | **001-35931** | **001-35931** | **001-35931** | **98-0667516** |
| **(State or other jurisdiction** <br>**of incorporation or organization)**<br>| **(Commission File Number)** | **(Commission File Number)** | **(Commission File Number)** | **(I.R.S. Employer Identification No.)** |
| | **300 East Lombard Street,** | **300 East Lombard Street,** | **300 East Lombard Street,** | |
|  | **Suite 1710** | **Suite 1710** | **Suite 1710** |  |
|  | **Baltimore,**  | **Baltimore,** <br> **MD** | **21202** |  |
| **(Address of principal executive office (US))** | **(Address of principal executive office (US))** | **(Address of principal executive office (US))** | **(Address of principal executive office (US))** | **(Address of principal executive office (US))** |
|  |  | **(443)** | **420-7861** |  |
| **(Registrant's telephone number, including area code)** | **(Registrant's telephone number, including area code)** | **(Registrant's telephone number, including area code)** | **(Registrant's telephone number, including area code)** | **(Registrant's telephone number, including area code)** |
|  |  | **N/A** |  |  |
| **(Former name or former address, if changed since last report)** | **(Former name or former address, if changed since last report)** | **(Former name or former address, if changed since last report)** | **(Former name or former address, if changed since last report)** | **(Former name or former address, if changed since last report)** |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the

following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

| | | |
|:---|:---|:---|
| **Securities registered pursuant to section 12(b) of the Act** | **Securities registered pursuant to section 12(b) of the Act** | **Securities registered pursuant to section 12(b) of the Act** |
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Ordinary Shares | CSTM | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in [sic] Rule 405 of the Securities Act of 1933 (§

230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new

or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 5.07** | **Submissions of Matters to a Vote of Security Holders** |

---

Constellium SE (the "Company") held its Annual General Meeting of Shareholders on May 21, 2026. The proposals

for the appointment of Ingrid Joerg and the re-appointment of John Ormerod to the Company's Board of Directors

for a period of three years following the Annual General Meeting, passed.

The Company's shareholders approved, on an advisory basis, "one year" as the frequency for holding an advisory

(non-binding) vote on the compensation of the Company's named executive officers. In light of such vote, the

Company has determined to hold the advisory (non-binding) vote on the compensation of the Company's named

executive officers every year. The results for the remainder of the proposals are as set forth below.

\* For the purposes of French law, broker non-votes are treated as abstentions. Therefore, in terms of the voting

results, broker non-votes, like other abstentions, were not counted as a vote cast on the applicable proposal.

The voting results are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| 1. | Ratification of the interim appointment of Ms. Ingrid Joerg as a director | Ratification of the interim appointment of Ms. Ingrid Joerg as a director | Ratification of the interim appointment of Ms. Ingrid Joerg as a director | Ratification of the interim appointment of Ms. Ingrid Joerg as a director |
|  | **<u>Voted For</u>** | **<u>Voted Against</u>** | **<u>Abstained</u>** | **<u>Broker Non-Votes\*</u>** |
|  | 97,942,587 | 320,964 | 80,305 | 10,462,884 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| 2. | Appointment of Ms. Ingrid Joerg as a director for a term of three years | Appointment of Ms. Ingrid Joerg as a director for a term of three years | Appointment of Ms. Ingrid Joerg as a director for a term of three years | Appointment of Ms. Ingrid Joerg as a director for a term of three years |
|  | **<u>Voted For</u>** | **<u>Voted Against</u>** | **<u>Abstained</u>** | **<u>Broker Non-Votes\*</u>** |
|  | 97,919,555 | 343,694 | 80,607 | 10,462,884 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| 3. | Re-appointment of Mr. John Ormerod as a director for a term of three years | Re-appointment of Mr. John Ormerod as a director for a term of three years | Re-appointment of Mr. John Ormerod as a director for a term of three years | Re-appointment of Mr. John Ormerod as a director for a term of three years |
|  | **<u>Voted For</u>** | **<u>Voted Against</u>** | **<u>Abstained</u>** | **<u>Broker Non-Votes\*</u>** |
|  | 82,318,163 | 15,907,876 | 117,817 | 10,462,884 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| 4. | Approval, on an advisory (non-binding) basis, of the 2025 compensation of the Company's named executive <br>officers | Approval, on an advisory (non-binding) basis, of the 2025 compensation of the Company's named executive <br>officers | Approval, on an advisory (non-binding) basis, of the 2025 compensation of the Company's named executive <br>officers | Approval, on an advisory (non-binding) basis, of the 2025 compensation of the Company's named executive <br>officers |
|  | **<u>Voted For</u>** | **<u>Voted Against</u>** | **<u>Abstained</u>** | **<u>Broker Non-Votes\*</u>** |
|  | 79,852,601 | 5,788,962 | 12,702,293 | 10,462,884 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| 5. | Advisory (non-binding) vote to hold an advisory (non-binding) vote on the compensation of the Company's <br>named executive officers <u>every year</u> | Advisory (non-binding) vote to hold an advisory (non-binding) vote on the compensation of the Company's <br>named executive officers <u>every year</u> | Advisory (non-binding) vote to hold an advisory (non-binding) vote on the compensation of the Company's <br>named executive officers <u>every year</u> | Advisory (non-binding) vote to hold an advisory (non-binding) vote on the compensation of the Company's <br>named executive officers <u>every year</u> |
|  | **<u>Voted For</u>** | **<u>Voted Against</u>** | **<u>Abstained</u>** | **<u>Broker Non-Votes\*</u>** |
|  | 98,273,291 | 31,220 | 39,345 | 10,462,884 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| 6. | Advisory (non-binding) vote to hold an advisory (non-binding) vote on the compensation of the Company's <br>named executive officers <u>every two years</u> | Advisory (non-binding) vote to hold an advisory (non-binding) vote on the compensation of the Company's <br>named executive officers <u>every two years</u> | Advisory (non-binding) vote to hold an advisory (non-binding) vote on the compensation of the Company's <br>named executive officers <u>every two years</u> | Advisory (non-binding) vote to hold an advisory (non-binding) vote on the compensation of the Company's <br>named executive officers <u>every two years</u> |
|  | **<u>Voted For</u>** | **<u>Voted Against</u>** | **<u>Abstained</u>** | **<u>Broker Non-Votes\*</u>** |
|  | 2,204,018 | 95,895,777 | 244,061 | 10,462,884 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| 7. | Advisory (non-binding) vote to hold an advisory (non-binding) vote on the compensation of the Company's <br>named executive officers <u>every three years</u> | Advisory (non-binding) vote to hold an advisory (non-binding) vote on the compensation of the Company's <br>named executive officers <u>every three years</u> | Advisory (non-binding) vote to hold an advisory (non-binding) vote on the compensation of the Company's <br>named executive officers <u>every three years</u> | Advisory (non-binding) vote to hold an advisory (non-binding) vote on the compensation of the Company's <br>named executive officers <u>every three years</u> |
|  | **<u>Voted For</u>** | **<u>Voted Against</u>** | **<u>Abstained</u>** | **<u>Broker Non-Votes\*</u>** |
|  | 2,195,685 | 95,903,685 | 244,486 | 10,462,884 |

---

---

| | | | |
|:---|:---|:---|:---|
| 8. | Approval of the statutory financial statements and transactions for the fiscal year ended December 31, 2025 | Approval of the statutory financial statements and transactions for the fiscal year ended December 31, 2025 | Approval of the statutory financial statements and transactions for the fiscal year ended December 31, 2025 |
|  | **<u>Voted For</u>** | **<u>Voted Against</u>** | **<u>Abstained</u>** |
|  | 107,959,981 | 8,556 | 838,203 |

---

---

| | | | |
|:---|:---|:---|:---|
| 9 | Approval of the consolidated financial statements and transactions for the fiscal year ended December 31, <br>2025 | Approval of the consolidated financial statements and transactions for the fiscal year ended December 31, <br>2025 | Approval of the consolidated financial statements and transactions for the fiscal year ended December 31, <br>2025 |
|  | **<u>Voted For</u>** | **<u>Voted Against</u>** | **<u>Abstained</u>** |
|  | 107,958,765 | 8,373 | 839,602 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| 10. | Discharge (quitus) of the directors, the Chief Executive Officer, and the Statutory Auditors of the Company in <br>respect of the performance of their duties for the fiscal year ended December 31, 2025 | Discharge (quitus) of the directors, the Chief Executive Officer, and the Statutory Auditors of the Company in <br>respect of the performance of their duties for the fiscal year ended December 31, 2025 | Discharge (quitus) of the directors, the Chief Executive Officer, and the Statutory Auditors of the Company in <br>respect of the performance of their duties for the fiscal year ended December 31, 2025 | Discharge (quitus) of the directors, the Chief Executive Officer, and the Statutory Auditors of the Company in <br>respect of the performance of their duties for the fiscal year ended December 31, 2025 |
|  | **<u>Voted For</u>** | **<u>Voted Against</u>** | **<u>Abstained</u>** | **<u>Broker Non-Votes\*</u>** |
|  | 84508508 | 13015971 | 819377 | 10462884 |

---

---

| | | | |
|:---|:---|:---|:---|
| 11. | Allocation of the results of the Company for the fiscal year ended December 31, 2025 | Allocation of the results of the Company for the fiscal year ended December 31, 2025 | Allocation of the results of the Company for the fiscal year ended December 31, 2025 |
|  | **<u>Voted For</u>** | **<u>Voted Against</u>** | **<u>Abstained</u>** |
|  | 108,658,184 | 9,365 | 139,191 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| 12. | Approval of the aggregate maximum amount of the directors' annual fixed fees | Approval of the aggregate maximum amount of the directors' annual fixed fees | Approval of the aggregate maximum amount of the directors' annual fixed fees | Approval of the aggregate maximum amount of the directors' annual fixed fees |
|  | **<u>Voted For</u>** | **<u>Voted Against</u>** | **<u>Abstained</u>** | **<u>Broker Non-Votes\*</u>** |
|  | 98,208,852 | 41,092 | 93,912 | 10,462,884 |

---

---

| | | | |
|:---|:---|:---|:---|
| 13. | Authorization to be given to the Board of Directors for the repurchase by the Company of its own shares in <br>accordance with article L. 225-209-2 of the French Commercial Code | Authorization to be given to the Board of Directors for the repurchase by the Company of its own shares in <br>accordance with article L. 225-209-2 of the French Commercial Code | Authorization to be given to the Board of Directors for the repurchase by the Company of its own shares in <br>accordance with article L. 225-209-2 of the French Commercial Code |
|  | **<u>Voted For</u>** | **<u>Voted Against</u>** | **<u>Abstained</u>** |
|  | 108,617,538 | 23,922 | 165,280 |

---

---

| | | | |
|:---|:---|:---|:---|
| 14. | Authorization to be given to the Board of Directors to reduce the Company's share capital by canceling shares <br>acquired pursuant to the authorization for the Company to repurchase its own shares in accordance with the <br>provisions of article L. 225-209-2 of the French Commercial Code | Authorization to be given to the Board of Directors to reduce the Company's share capital by canceling shares <br>acquired pursuant to the authorization for the Company to repurchase its own shares in accordance with the <br>provisions of article L. 225-209-2 of the French Commercial Code | Authorization to be given to the Board of Directors to reduce the Company's share capital by canceling shares <br>acquired pursuant to the authorization for the Company to repurchase its own shares in accordance with the <br>provisions of article L. 225-209-2 of the French Commercial Code |
|  | **<u>Voted For</u>** | **<u>Voted Against</u>** | **<u>Abstained</u>** |
|  | 108728505 | 20320 | 57915 |

---

---

| | | | |
|:---|:---|:---|:---|
| 15. | Authorization to be given to the Board of Directors to reduce the Company's share capital by canceling the <br>shares acquired by the Company pursuant to the provisions of article L. 225-208 of the French Commercial <br>Code | Authorization to be given to the Board of Directors to reduce the Company's share capital by canceling the <br>shares acquired by the Company pursuant to the provisions of article L. 225-208 of the French Commercial <br>Code | Authorization to be given to the Board of Directors to reduce the Company's share capital by canceling the <br>shares acquired by the Company pursuant to the provisions of article L. 225-208 of the French Commercial <br>Code |
|  | **<u>Voted For</u>** | **<u>Voted Against</u>** | **<u>Abstained</u>** |
|  | 108,724,554 | 24,190 | 57,996 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| 16 | Powers to carry out formalities | Powers to carry out formalities | Powers to carry out formalities | Powers to carry out formalities |
|  | **<u>Voted For</u>** | **<u>Voted Against</u>** | **<u>Abstained</u>** | **<u>Broker Non-Votes\*</u>** |
|  | 98,227,432 | 8,580 | 107,844 | 10,462,884 |

---

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits** |

---

 **(d) Exhibits**

The following exhibits are furnished with this report on Form 8-K:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 104 | The cover page of this Current Report on Form 8-K, formatted in Inline XBRL |

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be

signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CONSTELLIUM SE** | **CONSTELLIUM SE** |
|  | (Registrant) | (Registrant) |
| May 21, 2026 | By: | /s/ Jack Guo |
|  | Name: | Jack Guo |
|  | Title: | Executive Vice President &<br>Chief Financial Officer<br>|

---